Will Hologic Beat These Analyst Estimates?
Hologic (NAS: HOLX) is expected to report Q2 earnings on May 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hologic's revenues will grow 35.8% and EPS will increase 3.0%.
The average estimate for revenue is $639.8 million. On the bottom line, the average EPS estimate is $0.34.
Last quarter, Hologic recorded revenue of $631.4 million. GAAP reported sales were 34% higher than the prior-year quarter's $472.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.38. GAAP EPS of $0.01 for Q1 were 88% lower than the prior-year quarter's $0.08 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 61.3%, 120 basis points worse than the prior-year quarter. Operating margin was 13.1%, 430 basis points worse than the prior-year quarter. Net margin was 0.5%, 390 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $2.62 billion. The average EPS estimate is $1.58.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 671 members out of 691 rating the stock outperform, and 20 members rating it underperform. Among 162 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 156 give Hologic a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.82.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.
The article Will Hologic Beat These Analyst Estimates? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.